Minister of Information and Communication Technology (MICT), Peya Mushelenga, has expressed concern about what he termed ‘lazy journalists’, urging them to carry out their duties with the utmost professionalism.
Mushelenga made these remark at a breakfast meeting with news editors in the capital on Wednesday.
He said some journalists nowadays are too lazy to even take notes when someone is speaking at an event, and would rather wait for a copy of the speech from a minister.
‘Journalists do not want to read readily available information and instead want to take a shortcut or ask someone when such knowledge is easily accessible. Sometimes you give journalists printed copies of a speech, and they still come up to you and ask what was said, even though this is freely available information. If you read the hard copy, the information is there,’ Mushelenga said.
He further stated that when he is hesitant to answer reporters, it is not because he does not want to answer them, but because he wants to assist them in doing their jobs as media practitioners.
‘The MICT office gives pdf formats to journalists, not hard copies,’ he added.
At the breakfast meeting, the minister further emphasised the importance for all stakeholders to participate in order to make the Editors’ Forum of Namibia a success.
Ndasilohenda Katangolo-Nakashwa, a 37-year-old communal farmer from the Kunene Region’s Opuwo Rural Constituency, has won the 2023 Capricorn Foundation Food Waste Challenge.
She is the overall winner, receiving a N.dollars 100 000 cash prize from Capricorn Foundation, a N.dollars 50 000 brand package from Synergi, and six months of mentorship and coaching from Business Box Windhoek.
This announcement follows on the pitches made by the top five finalists on 22 June to a panel of judges.
Marlize Horn, Capricorn Foundation Executive Officer, stated during the ceremony on Thursday in Windhoek that Namibia suffers from severe hunger, ranking 78th out of 116 nations in the 2022 Global Hunger Index.
She said the Capricorn Foundation Food Waste Challenge was launched in April 2023 and called for innovative and sustainable solutions to create or expand self-sufficient social enterprises (businesses) to address the issue of food waste in Namibia and create employment for Namibians to combat these issues.
“The Capricorn Foundation remains committed to being a Connector of Positive Change and, apart from the winning solution and the many other innovative ideas that were submitted, the Food Waste Challenge provided a platform to create awareness of the issue of food waste and support social entrepreneurs in their potential to solve community-based problems and create jobs,” she said.
Katangolo-Nakashwa, the proprietor of Ndinandali Farm, stated that the farm’s goal is not only on profit but also on promoting food security and reaching the most vulnerable populations.
“The Capricorn Foundation Food Waste Challenge has been an amazing experience and I look forward to collaborating with the other finalists,” she said.
Ndinandali Farm, an agricultural venture dedicated to preserving nutritional value and extending the shelf life of fresh produce, has revolutionised marketing and distribution methods. Their dried vegetables, including spinach, tomato and cabbage, have become popular food staples in rural villages and towns.
Rikus Grobler, Capricorn Group’s Manager of Innovation and project coordinator of the challenge, expressed appreciation for the 152 submissions and encouraged their execution.
He praised the ideas focusing on sustainability, longer shelf life, nutritional preservation, and alternative protein sources for their potential to benefit Namibians. Grobler thanked participants and partners (Skild, Business Box, Namibia Media Holdings, Synergi and Gondwana Care Trust) and emphasised their contributions to the initiative’s success.
Namibia’s T44 sprinter, Denzel Namene and T13 sprinter Johannes Nambala on Tuesday missed out on silverware after finishing fifth and sixth in their respective events at the 2023 Paris World Para Athletics Championships underway in France.
The 2023 International Paralympic Committee (IPC) World Para Athletics Championships which runs from 08 to 17 July, has over 1 300 athletes from 107 nations competing for 168 medals.
On Tuesday night, Namene came fifth in the final of the 100m with a time of 12.45 seconds, while Nambala ran a seasonal best of 11.05 seconds, which was not good enough for a medal as he crossed the line sixth.
T13 100m world record holder, Ageze Salum Kashafali of Norway, won the gold with a championship record of 10.45 seconds.
Meanwhile, Namibian T12 sprinter, Lahja Ipinge, who made her debut at the world athletics championships, was disqualified in the 400m heats for a false start and Namibia’s T11 400m silver medallist Lahja Ishitile also failed to progress to the final of the 100m after finishing second in the semi-finals.
Only the winners of the T11 100m heats and one of the fastest times from the three heats qualified for the final.
On Wednesday morning, T47 athlete Bradley Murere missed out on a medal in the long jump event after finishing 15th with a season-best of 5.62m. Robiel Sol Cervantes of Cuba won the gold with a championship record throw of 7.63m.
Still on Wednesday, T37 sprinter Petrus Karuli, who has thus far found the going tough at the championships, had a change in fortunes as he reached the final of the 400m after finishing second in his heat. Karuli clocked a time of 56.97 seconds, while the heat winner Yaroslav Okapinskyi of Ukraine clocked 54.89 seconds.
After six days of competition, Namibia has one silver medal.
In the previous edition of the IPC World Para Athletics Championships held in 2019 in Dubai, United Arab Emirates, Team Namibia won two medals which were gold and bronze, both from Johannes Nambala in the 400m and 100m sprints.
The major international multi-sport event involves athletes with a range of disabilities and is governed by the International Paralympics Committee.
The Ministry of Higher Education, Technology and Innovation (MHETI) has inaugurated the interim council members for the Namibia University of Science and Technology (NUST).
In statement issued on Thursday, Minister of Higher Education, Technology and Innovation, Itah Kandjii-Murangi, announced that the selected individuals were appointed on Wednesday and will serve until a substantive board is inaugurated.
The ministry’s public relation officer, Selma Ngola, stated that the individuals selected to be chairperson and deputy chairperson are; Leake Hangala and Nora Ndopu.
The board includes; Uazuva Kaumbi, Norah Ndopu, Leake Hangala, Emilia Ngikembua, Shafishuna Nujoma, Stanley Shanapinda, Detlof Oertzen, Rachel Kalipi, Kadiva Hamutumwa, Alfred van Kent and Flora Gaes, Ngola said.
PETAH TIKVA, Israel and TYSONS CORNER, Va., July 12, 2023 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in Digital Intelligence (“DI”) solutions for the public and private sectors, today announced it will report its second-quarter 2023 financial results before market open on Tuesday, August 8, 2023.
Later that same morning, Cellebrite will host a live conference call and webcast to review the Company’s financial results for the first quarter of 2023 and discuss its full-year 2023 outlook. Pertinent details include:
In conjunction with the conference call and webcast, historical financial tables and supplemental data will be available on the quarterly results section of Company’s investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results. A transcript of the call will be added to this page along with access to the replay of the call.
About Cellebrite
Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more, visit us at www.cellebrite.com and https://investors.cellebrite.com.
Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations [email protected]
+1 404.804.5910
This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the acceptance of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID-19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; political and reputational factors related to Cellebrite’s business or operations; risks relating to estimates of market opportunity and forecasts of market growth; Cellebrite’s ability to properly manage its growth; risks associated with Cellebrite’s credit facilities and liquidity; Cellebrite’s reliance on third-party suppliers for certain components, products, or services; challenges associated with large transactions and long sales cycle; risks that Cellebrite’s customers may fail to honor contractual or payment obligations; risks associated with a significant amount of Cellebrite’s business coming from government customers around the world; risks related to Cellebrite’s intellectual property; security vulnerabilities or defects, including cyber-attacks, information technology system breaches, failures or disruptions; the mishandling or perceived mishandling of sensitive or confidential information; the complex and changing regulatory environments relating to Cellebrite’s operations and solutions; the regulatory constraints to which we are subject; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on March 29, 2022,as amended on April 14, 2022 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster
SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE). Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using NVIDIA cloud services.
“Our collaboration with NVIDIA represents two best-in-class companies coming together to help solve one of the world’s most difficult challenges, drug discovery,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “With our powerful dataset and NVIDIA’s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space.”
Recursion plans to utilize its vast proprietary biological and chemical dataset, which exceeds 23 petabytes and 3 trillion searchable gene and compound relationships, to accelerate the training of foundation models on NVIDIA DGX Cloud for possible commercial license/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery. NVIDIA will also help optimize and scale Recursion foundation models leveraging the NVIDIA AI stack and NVIDIA’s full-stack computing expertise. BioNeMo was announced earlier this year as a cloud service for generative AI in drug discovery, offering tools to quickly customize and deploy domain-specific, state-of-the-art biomolecular models at-scale through cloud APIs. Recursion anticipates using this software to support its internal pipeline as well as its current and future partners.
“Generative AI is a revolutionary tool to discover new medicines and treatments,” said Jensen Huang, founder and CEO of NVIDIA. “We are delighted to collaborate with Recursion’s world-class team, which is doing pioneering work in digital biology and chemistry with NVIDIA DGX and NVIDIA AI software to accelerate the development of the world’s largest biomolecular generative AI models and speed drug discovery for biotech and pharmaceutical companies.”
Recursion, through its recent acquisition of Valence Discovery, aims to accelerate the development of new technologies to feed the biopharma industry, while simultaneously democratizing access to large-scale models that have maximum impact in drug discovery.
About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the acceleration and advancement of development of AI foundation models, as well as optimizing, licensing, and distributing such models; using BioNeMo software to support Recursion’s internal pipeline and well as Recursion’s current and future industry partners; Recursion accelerating development of new technologies through its Valence Discovery acquisition; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Cloud
